Alzheimer’s disease

  • Most common form of forgetfullness
  • Commonly seen in elder people
  • > 37 million sufferers worldwide and a global cost of over $600 billion.
  • Currently no reliable method of diagnosis 

Technology to the rescue !!!

Scientists at the University of Leeds have developed a new technology that could form the basis of a simple blood test for Alzheimer’s disease. The new biosensor measures harmful clusters of the protein amyloid-beta, an early indicator of Alzheimer’s disease. The study is published in the Biosensors and Bioelectronics journal. The physicians today can think of biosensors as a effective medium to diagnose Alzheimer’s disease and start addressing it early. Below pic depicts the biosensor used.



The NADINE project aims at the development of a diagnostic tool able to detect in blood as early as possible, and at a cost compatible with large scale screening, emerging neurodegenerative diseases (e.g. Alzheimer’s Disease), and thus aid in the selection of the best treatment. None of current methods is able to achieve such a differentiation. The project thus has an immense impact for health, quality of life and economy. The NADINE project will involve radical innovations in microfluidics, nanoparticles, electrophoresis protein analyses, analytic chemistry and bioinformatics.

It will develop and integrate new technologies towards a fully automated lab-on-chip system for the simultaneous quantitative analysis of a multiplicity of proteins, peptides and their variants, down to concentrations in the picomolar range directly from plasma. In particular, the system will, for the first time, combine in a single automated operation protein microarray and microchannel high resolution electrophoresis directly from clinical samples. – for more reading !!!